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Abstract
Background Effective anticancer therapy is thought to involve induction of tumour cell death through apoptosis and/or necrosis.
[18F]ICMT-11, an isatin sulfonamide caspase-3/7-specific radiotracer, has been developed for PET imaging and shown to have
favourable dosimetry, safety, and biodistribution. We report the translation of [18F]ICMT-11 PET to measure chemotherapy-
induced caspase-3/7 activation in breast and lung cancer patients receiving first-line therapy.
Results Breast tumour SUVmax of [
18F]ICMT-11 was low at baseline and unchanged following therapy. Measurement of M30/
M60 cytokeratin-18 cleavage products showed that therapy was predominantly not apoptosis in nature. While increases in
caspase-3 staining on breast histology were seen, post-treatment caspase-3 positivity values were only approximately 1%; this
low level of caspase-3 could have limited sensitive detection by [18F]ICMT-11-PET. Fourteen out of 15 breast cancer patients
responded to first–line chemotherapy (complete or partial response); one patient had stable disease. Four patients showed
increases in regions of high tumour [18F]ICMT-11 intensity on voxel-wise analysis of tumour data (classed as PADS); response
was not exclusive to patients with this phenotype. In patients with lung cancer, multi-parametric [18F]ICMT-11 PET and MRI
(diffusion-weighted- and dynamic contrast enhanced-MRI) showed that PET changes were concordant with cell death in the
absence of significant perfusion changes.
Conclusion This study highlights the potential use of [18F]ICMT-11 PET as a promising candidate for non-invasive imaging of
caspase3/7 activation, and the difficulties encountered in assessing early-treatment responses. We summarize that tumour re-
sponse could occur in the absence of predominant chemotherapy-induced caspase-3/7 activation measured non-invasively across
entire tumour lesions in patients with breast and lung cancer.
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Background
Cell death, is recognised for the constant regulation and har-
mony of biological systems and is known to occur by several
mechanisms, predominantly necrosis and apoptosis. Necrotic
cell death is characterised by a non-specific process of events
resulting in plasma membrane rupture and a localised inflam-
matory response around the surrounding cells and tissues.
Apoptosis (programmed cell death, first described by Kerr
and colleagues [1, 2]), however, is a precise series of well-
executed events with upstream regulators and downstream
effector components [3, 4], leading to the systematic dismem-
berment of the cell by Bapoptotic triggers^. The Bapoptotic
triggers^ are kept in balance by pro- and anti-apoptotic regu-
latory proteins, including members of the Bcl-2 family
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[3]. One of the key players in the execution of apoptosis is a
family of caspases (cysteine aspartate specific proteases) [4].
Caspases 8 and 9, known as the initiator caspases, are respon-
sible for initiating a cascade of proteolysis by cleavage of pro-
caspases 3, 6, and 7 to their activated form. The controlled
demolition of cellular components resulting in DNA fragmen-
tation is unique to apoptosis, and one that is driven by caspase
3, a central effector caspase. It is this unique feature of
caspase-3 that permits its potential use as a non-invasive bio-
marker of apoptosis [5].
Imaging the apoptotic process may prove to be invaluable
for the following reasons: a) by enabling anti-cancer therapy
response assessment at earlier time-points than current re-
sponse criteria allows with conventional imaging, apoptosis
imaging may aid the decision to implement changes to treat-
ment in the context of drug resistance sparing the unwanted
side-effects of ineffective treatment, and b) secondly, by
allowing for the pharmacodynamic assessment of drugs that
target the apoptotic machinery in early-phase trials during
drug development.
There has been a handful of pre-clinical and clinical PET
imaging studies attempting to image molecular and biochemical
events of the apoptotic process [6–14]. Studies with [18F]ML-10
[9, 15–17] and [99mTc]Annexin V [11, 12, 18–20] showed prom-
ising results in humans. A study of [18F]ML-10 [9]— a member
of the aposense family of biomarkers that measures ‘apoptotic
imprint’— in human subjects reported favourable dosimetry and
biodistribution, and binding to apoptotic sites in testicular tissue
of mice, confirmed by terminal deoxynucleotidyl transferase
(TdT) dUTP nick-end labeling (TUNEL) of apoptotic cells; ini-
tial studies reported correlation of early changes of tumour
[18F]ML-10, and later changes in anatomical tumour dimension
following radiotherapy [16, 17].
Annexin V, a 36 kDa calcium-dependent protein with the
ability to bind to cells during all stages of the apoptotic pro-
cess, has high affinity for phosphatidylserine (a phospholipid,
normally located on the inner leaflet of cell membranes).
During apoptosis, phosphatidylserine is exposed to the extra-
cellular surface and provides an opportunity for annexin V
binding. To date, [99mTc]HYNIC-annexin V has been investi-
gated widely for the imaging of apoptosis, and has provided
invaluable information in several disease settings [11, 12, 18,
19]. Both [18F]ML-10 and [99mTc]Annexin V imaging, how-
ever, pose limitations. [18F]ML-10 remains undefined in its
specific target and [99mTc]Annexin V in its non-specific up-
take, which has proved difficult in distinguishing between
apoptosis and necrosis.
Clinical studies evaluating apoptosis in breast cancer ther-
apy have shown an increase in apoptosis within biopsies taken
at 24 h post-chemotherapy (comparing six cycles of
epirubicin, cisplatin, and fluorouracil with six cycles of doxo-
rubicin and cyclophosphamide) compared to baseline
[21–24], as well as at 48, 72, and 96 h post-treatment
(combination of epirubicin, cisplatin, and fluorouracil, doxo-
rubicin and cyclophosphamide and weekly paclitaxel) [25]. In
the small numbers of patients studied, the authors highlighted
the wide variation of changes in apoptosis and or/necrosis and
importantly, no correlation of the changes with clinical re-
sponse to treatment.
Breast cancer is, to an extent, the ideal clinical setting to
obtain tissue pre- and post-therapy. Biopsies offer a snapshot
of caspase activation at microscopic levels; however, PETand
MRI provide dynamic and perhaps more robust non-invasive
methods for assessment of apoptosis across the entire lesion
volume. The fundamental requirements of any PET
radiolabeled probe are ease of synthesis, robust and reproduc-
ible facile radiolabelling procedure, and high specificity and
selectivity. [18F](S)-1-((1-(2-fluoroethyl)-1H-[1,2,3]-triazol-
4-yl)methyl)-5-(2(2,4-difluorophenoxymethyl)-pyrrolidine-1-
sulfonyl), [18F]ICMT-11 (Fig. 1a), an activated caspase-3/7
specific PET imaging radiotracer, was designed from a library
of isatin-5-sulfonamides, a chemical class known to have cas-
pase inhibitory activity. With regard to the mechanism of ac-
tion in relation to selectivity for binding activated caspase-3/7,
the dicarbonyl functionality of isatin sulfonamides, including
[18F]ICMT-11, is thought to form an intracellular enzyme–
tracer complex with the cysteine residue of the active site of
caspase-3/7 — forming a thiohemiketal via the electrophilic
C-3 carbonyl of the isatin sulfonamide and the nucleophilic
cysteine thiol functionality [26]. [18F]ICMT-11 was selected
for further evaluation, due to its subnanomolar affinity for
activated caspase-3, high metabolic stability, reduced lipophi-
licity, and facile radiolabelling [27]. Here, we report the results
of the first clinical study investigating [18F]ICMT-11 as a non-
invasive biomarker to assess tumour apoptosis in locally ad-
vanced breast cancer pre- and post-first-cycle of neo-adjuvant
chemotherapy (NCT), and in locally advanced lung cancer
patients receiving chemotherapy as first-line treatment.
Materials and methods
Radiopharmaceutical preparation
[18F]ICMT-11 synthesis and radiolabelling was performed by
Imanova Ltd., as previously described [28].
Patients
Two independent phase 1 non-randomised open-label pro-
spective feasibility studies (breast and lung cancer) were re-
cruited from 2013 to 2016. The aim of this study was to assess
the effect of chemotherapy on [18F]ICMT-11 uptake by PET
and relationship between this variable and blood and tissue
activated caspase-3/7 markers. Inclusion criteria in the breast
cohort required patients 18 years or older, newly diagnosed
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with locally advanced potentially operable breast cancer re-
ceiving NCT followed by surgery. At least one measurable
breast lesion ≥ 20 mm was required on conventional imaging.
Patients were excluded from the study if they had received any
chemotherapy, immunotherapy, biologic therapy, or investiga-
tional therapy within 14 days prior to the first dose of
[18F]ICMT-11 injection. Exclusion also applied if the subject
was undergoing occupational monitoring of ionising radiation
exposure, was lactating or pregnant, or was taking any
anticoagulation therapy, a prolonged prothrombin time, or
had a positive Allen’s test.
All breast patients, as per standard routine diagnostic and
staging procedures, had a pre-treatment core-needle biopsy
and ultrasound (USS) for histological confirmation with char-
acterisation of hormone receptor status alongside imaging
with mammogram, and if indicated an MRI of the breasts.
Patients had a sentinel lymph node biopsy prior to NCT if
deemed appropriate by their clinical team. NCT consisted of
six cycles of FEC-T (5-f luorouraci l , epirubicin,
cyclophosphamide and docetaxel) alongside trastuzumab
(Herceptin) in those with HER2-positive breast cancer.
Patients were treated at Imperial College Healthcare NHS
Trust, and one patient was treated at their local oncology unit.
Clinical response using RECIST 1.1 after three cycles of NCT
using USS and after six cycles of chemotherapy on surgical
histopathology specimens (post wide local excision or mas-
tectomy ± axillary lymph node clearance) was documented.
Patients underwent a baseline dynamic [18F]ICMT-11 PET/
CT prior to start of NCT for 65 min followed by a repeat
PET/CT scan performed 24–48 h (early) or within 2–14 days
(late) post-chemotherapy and repeat breast biopsy within 24 h
of the second PET/CT to correlate apoptosis in breast tissue
utilising cleaved (active) caspase-3 staining by immuno-
histochemistry.
In the small cohort of lung patients (n = 2), subjects diag-
nosed with non-small cell lung cancer undergoing platinum-
based chemotherapy treatment (both patients were treated
with pemetrexed and cisplatin) were enrolled. At least one
measurable lung lesion ≥ 20 mmwas required on convention-
al imaging. Patients were required to have a PET/CT, as well
as DW- and DCE-MRI at baseline and post-chemotherapy
(24–48 h (early) and within 6–8 days (late) post-treatment).
A baseline DW- or DCE-MRI over the area of interest was
followed by a 61-min dynamic [18F]ICMT-11 PET/CT scan.
The Harrow and Westminister London Research Ethics
Committees approved the breast and lung study, respectively.
All subjects signed a written informed consent form. The
study was conducted according to the Declaration of
Helsinki. The administration of radioactivity was approved
by the Administration of Radioactive Substances Advisory
Committee, U.K.
Imaging acquisition
Images were acquired on a Biograph 6 TruePoint PET/CT
scanner (with TrueV; extended field of view [Siemens]) with
21.6 cm axial and 60.5 cm transaxial fields of view. Patients in
both studies underwent an attenuation CT scan (CT settings:
a b
Fig. 1 Chemical structure of [18F]ICMT-11 and) study design in breast
and lung cancer cohorts. a Schematic diagram of chemical structure of
[18F]ICMT-11. b Study design in breast cancer patients receiving neo-
adjuvant chemotherapy. Patients underwent a baseline and follow-up scan
with a repeat second breast biopsy under USS guidance, within 24 h of
the second PET/CT scan. The cohort of lung cancer patients recruited to
study all received first-line chemotherapy (combination chemotherapy
with a platinum-based compound — Cisplatin). [18F]ICMT-11 PET/CT
and MRI (DW and DCE) were performed at three time-points (baseline,
follow-up at 24–48 h, and within 6–8 days post-chemotherapy. FEC = 5-
fluorouracil, epirubicin and cyclophosphamide, USS = ultrasound, MRI
magnetic resonance imaging, DW = diffusion-weighted, DCE = dynamic
contrast-enhanced
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tube potential, 130 kV; exposure, 15 effective mAs; pitch 1.5;
slice thickness, 5 mm; rotation time, 0.6 s; effective dose of
2.5 mSv) of the thorax before administration of [18F]ICMT-11
injection. [18F]ICMT-11 was injected with a target dose of
300 MBq (maximum dose 370 MBq) as a slow bolus in 1–
20 mls of saline over 30s. Dynamic PET imaging was per-
formed in a single bed position over 65 min with blood and
plasma radioactivity measurements at specified time-points.
Data were binned into 35 frames and reconstructed using the
ordered subset expectation maximization algorithm (3 itera-
tions and 21 subsets). In the lung cohort, dynamic PET imag-
ing was performed in a single bed position over 61 min. Data
were binned into 36 frames and reconstructed using the or-
dered subset expectation maximization algorithm (3 iterations
and 21 subsets). Radioactive blood data were taken but were
not analysed in this study.
Image analysis
All volumes of interest on PET/CTwere outlined manually on
Hermes (Hermes Diagnostics, Stockholm, Sweden) by a sin-
gle investigator (SD) to avoid any interobserver variation. For
the breast study, volumes of interest (VOIs) were drawn on
fused PET/CT datasets by outlining the whole primary breast
tumour and any involved axillary lymph nodes [regions of
interest (ROIs) over several slices]. VOIs were also drawn
using a 2-cm fixed sphere to outline contralateral breast tissue,
normal lung, bone, muscle, and aorta. In the lung study, VOIs
were drawn outlining the primary lung tumour lesion, normal
contralateral lung, bone, muscle, and aorta. SUV60ave,
SUV60max, tumour to breast ratio (TBR60max) and tumour to
muscle ratio (TMR60max) were obtained at baseline and post-
chemotherapy in both studies.
In both studies, all VOIs were also outlined on fused PET/
CT images to create binary object masks using Analyze soft-
ware (version 11; Biomedical Imaging Resource, Mayo
Clinic). The object masks created for tumour and lymph
nodes, alongside respective dynamic PET data, were used
within Matlab 16a (The MathWorks®) for analysis and char-
acterisation of the VOIs by voxel intensities sorting. Voxel-
wise analysis of PET data was done as previously described
[29]. Briefly, this involved extraction of all the voxels within
each VOI and sorting as per their intensity frequency. PET-
based voxel intensity sorting (PVIS) identifies any shifts in
voxels, as would otherwise be difficult to observe by using
only ROI analyses, where any spatially discrete areas of effect
may be averaged. Any shifts observed (higher intensity
voxels) were presumed to be in keeping with apoptosis and
shifts to lower intensity voxels representing necrosis. The
highest voxel intensities (taken as a cut-off at the 95th percen-
tile) are more indicative of high radiotracer retention than the
voxel mean, and were taken to biologically represent apopto-
tic cells.
Histogram analysis was then performed using in-house
software developed in Matlab 15a (The MathWorks(R)), to
calculate first-order statistics.
DW-MRI and DCE MRI
DW-MRI and DCE-MRI image analyses is described in
Supplementary materials and methods 1).
Cytokeratin-18 measurements
Blood samples were taken in breast patients to measure CK-
18. Two samples, each 7.5 mls, of blood from all patients were
taken at baseline and at follow-up scan to measure M65 (mea-
suring caspase-cleaved and intact CK-18) and M30 (measur-
ing caspase-cleaved CK-18) using ELISA kits obtained by
PEVIVA (BIOAXXESS, UK) (Supplementary material and
methods 2).
Cleaved (active) caspase-3 immunohistochemistry
A core biopsy was taken post-chemotherapy by a consultant
interventional radiologist within 24 h of the second
[18F]ICMT-11 PET/CT scan. All diagnostic and research
breast biopsies obtained were processed as previously de-
scribed [8] (Supplementary materials and methods 3).
Data and materials availabilityAll tissue stained for caspase-3
expression and cytokeratin analyses were stored with ECMC,
Imperial College, London, UK. All materials received local
tissue bank approval.
Results
Radiopharmaceutical
The radiolabelling of [18F]ICMT-11 was performed as previ-
ously described [28]. Radiochemical purity was > 99% on
completion of synthesis with a mean (± SD) specific activity
of 1373 ±1605 GBq/μmol (range, 199-9317 GBq/μmol) and
pH of 5.02 ± 0.22 (range 4.57–5.66). The mean (range) doses
injected in all breast patients pre- and post-chemotherapy were
335.6 MBq (278.4–353.3 MBq) and 343.1 MBq (282.4–
359.1 MBq).
Patients
The study was designed: (a) in breast cancer to assess the
effect of chemotherapy on [18F]ICMT-11 uptake correlated
with blood cytokeratin-18 assessment and biopsy-derived cas-
pase-3/7 tissue expression within 24 h of the first dose of
neoadjuvant FEC-T treatment, and (b) in lung cancer to
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measure the longitudinal effect of first-line chemotherapy on
[18F]ICMT-11 correlated with diffusion-weighted and dynam-
ic contrast-enhanced magnetic resonance imaging (DW- and
DCE-MRI) at each time point; notably, the latter was more
difficult to recruit to, as a result only descriptive data are pre-
sented. A total of 23 patients were recruited, 20 breast cancer
patients and three lung cancer patients. Seventeen patients
were evaluable (15 breast cancer patients, all of whom were
female, and two lung cancer patients, both male). Five breast
patients withdrew from the study (two due to tracer failure,
two due to patient’s personal decision, and one due to needle
phobia), and one lung patient also withdrew (due to extreme
fatigue). Study design and patient characteristics are shown in
Fig. 1b and Table 1 respectively. All breast patients had a
diagnosis of invasive ductal carcinoma. Ten patients were
found to have positive axillary lymph nodes on ultrasound
(USS) and/or sentinel lymph node biopsy. All 15 patients
completed a total of six cycles of FEC-T (three cycles of 5-
fluorouracil, epirubicin, and cyclophosphamide, followed by
three cycles of docetaxel). Four patients then commenced
trastuzumab (Herceptin) concomitantly with docetaxel, after
the first three cycles of FEC chemotherapy, for 1 year, as per
standard local hospital guidelines. Fourteen patients received
radiotherapy post-surgery, and one patient did not require ra-
diotherapy. Oestrogen (ER), progesterone (PR), and human
epidermal growth factor (HER2/neu) receptor status are doc-
umented in Table 1. Response was measured after three cycles
of NCT by USS and after six cycles on histopathology at
surgery. Fourteen out of 15 patients were classified as re-
sponders — partial response (PR) or complete response
(CR) post-treatment — and one patient had stable disease
(SD); no patient showed evidence of disease progression.
Both lung cancer patients had a diagnosis of non-small
cell carcinoma (adenocarcinoma). Clinical response in the
patients with lung cancer were reported with computerized
tomography (CT) using RECIST 1.1 [30] midway through
their chemotherapy and at the end. One lung patient had a
PR post four cycles of chemotherapy and proceeded to
radiotherapy treatment (55Gy in 20 fractions over 4 weeks),
the second patient, had a PR after three cycles and com-
pleted five cycles with SD after initial PR. This patient
subsequently died due to infection, unrelated to tumour
or treatment received.
[18F]ICMT-11 uptake in breast tumours at baseline
and post-chemotherapy
[18F]ICMT-11 was well tolerated by all patients, with no im-
mediate or delayed complications observed. The median time
(range) between baseline [18F]ICMT-11 PET/CT and start of
NCT in breast patients was 6 days (1–14 days), and that be-
tween first cycle of NCT and post-treatment [18F]ICMT-11
PET/CT was 12 days (24 h–14 days).
All primary tumours and involved axillary lymph nodes
were visible on conventional imaging and PET; however,
not all lesions demonstrated uptake on [18F]ICMT-11 PET
(Fig. 2a). For analysis, patients were divided into early (24–
48 h) and late (2–14 days) imaging post-chemotherapy. There
were four patients in the early imaging group and 11 in the late
imaging group. The mean and maximum SUV at 60 min
(SUV60ave and SUV60max) pre- and post-chemotherapy are
illustrated in Fig. 2b and c. The median (range) pre-
treatment SUV60ave and pre-treatment SUV60max were 0.56
(0.33–0.94) and 0.91(0.53–1.24) respectively. Post-treatment
SUV60ave and post-treatment SUV60max were 0.50 (0.38–
1.07) and 0.75 (0.41–1.59) respectively. Pre- and post-
chemotherapy ratios (± standard deviation, SD) of tumour-
to-normal breast tissue (TBR60max), were 3.65 (± 1.71), 3.34
(± 1.52); corresponding tumour-to-muscle ratios (TMR60max)
were 1.63 (± 0.43), 1.57 (± 0.49) respectively. Time–activity
curves for breast tumour and background tissue are provided
(Supplementary Fig. S1).
Seven first-order statistics were extracted (mean, standard
deviation, min, max, range, skew, and kurtosis), and none
showed a change in the variables, irrespective of whether they
were in the early or late imaged breast tumour group (Fig. 2d).
Voxel-wise analysis of [18F]ICMT-11 PET imaging data
As previously described [29], the analysis of apoptosis in PET
imaging at the tumour level using a PET-based voxel intensity
sorting (PVIS) approach allows for the overall spatial distri-
bution of voxel intensities within the tumour to be assessed;
higher Δ intensity in treated tumours compared to baseline
(right shift) is assigned PVIS apoptosis-dominant signature
(PADS), while lower Δ intensity (left shift) is assigned PVIS
necrosis-dominant signature (PNDS).
Four patients (e.g., patients 1 and 2 in Fig. 2) displayed
PADS (Fig. 3a); patient 3 in particular had a substantial right
shift in voxel intensities. Mean percentage shift in voxel in-
tensities for all four patients was 71%, and all had a PR after
three cycles of chemotherapy on USS and after six cycles
confirmed on histopathological correlation at surgery. The ar-
ea under the curve (AUC) differences for all patients (num-
bered 1–15) are shown (Fig. 3c). Thus, it appears that despite a
lack of change in SUV60ave there were regional changes in
tumour radiotracer uptake.
Of the 11 patients that did not demonstrate PADS, nine
displayed ≥ 25% lower voxel intensities post-treatment indi-
cating a PNDS. Examples of patients with PNDS— patients 5
(with post-treatment imaging at 24 h) and 6 (post-treatment
imaging at 6 days) are shown in Fig. 3b. The mean percentage
shift in voxel intensities was 68%; eight out of the nine pa-
tients had either a PR or CR post-chemotherapy, while one
patient (patient 10) had SD (Fig. 3d), suggesting that either
PADS or PNDS can be associated with response to therapy.
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The remaining two patients (exemplified by patient 14)
showed no change in voxel intensity (Fig. 3b), despite show-
ing PR to therapy. Notably, a snapshot of tumour [18F]ICMT-
11 localisation is detected by our methodology; thus, presently
we do not know whether the necrosis-dominant signature or
indeed the no change in voxel intensities despite PR/CR, rep-
resents outright necrosis or a dynamic transition of cell death
via an apoptosis dominant signature. In the cohort of patients
studied, no patients demonstrated progressive disease.
Cytokeratin-18 and caspase cleaved cytokeratin-18
All breast patients had blood taken for cytokeratin-18 (CK-18)
analysis. Circulating full-length (M65) and caspase-cleaved CK-
Table 1 Patient characteristics
The median age (mean; range) of all patients: 54y (52; 37-67y), median weight 71.9 kg (73; 52.3-95.3 kg)
Light grey shading (patients 1-4, found to show a predominant apoptotic signature)
Mid-grey shading (patients 5-13, found to show a predominant necrotic and/or necrotic/apoptotic signature)
Dark grey shading (patients 14 and 15, found to show neither a predominant apoptotic or necrotic shift)
IDC Invasive ductal carcinoma, HG DCIS High grade ductal carcinoma in-situ, IM DCIS Intermediate grade ductal carcinoma in-situ, ER Oestrogen
receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor 2
*AJCC staging (7th edition) used for TNM staging in breast and lung cancer
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18 (M30) fragments were assessed by ELISA pre- and post-
treatment at the time of the PET scan. Typical data are shown
in Fig. 3e. Ratios of cleaved to total CK-18 varied considerably
in this cohort of breast patients (Supplementary Fig. S2,
Supplementary Table S2), with the lowest ratio post-
chemotherapy 0.27 observed in patient 10, in whom there was
no response to NCT. The median pre- and post-chemotherapy
values ofM65were 141.5U/l (range 50.3–359.7), and 180.8U/l
(range 66.9–369.7), and those for M30 were 78.8 U/l (range
32.2–207.9) U/L and 102.7 U/l (range 47.8–207.7) respectively.
Overall M30 or M65 did not correlate with PADS or PNDS
(Fig. 3f). Patient 3, who had the highest PADS, also showed
the only consistent increase of M30/M65 ratio, increasing from
0.35 pre-chemotherapy to 0.52 post-chemotherapy, perhaps
suggesting that the levels of apoptosis or necrosis were not suf-
ficiently high to generate robust changes of M30/M65 in blood.
Cleaved caspase-3 expression
Acknowledging that pre- and post-treatment biopsies could have
been taken from different parts of the tumour, we assessed if
there was some general association between the PVIS data and
histopathology in the breast patients. All diagnostic (pre-) and
post-chemotherapy biopsies were stained for cleaved (active)
capsase-3 expression. The diagnostic tumour blocks of two pa-
tients (patients 2 and 5) were not available. Typical cleaved
caspase-3 immunostains in patients assigned PADS and PNDS
are shown in Fig. 4a and b. Whole tissue mount analysis of
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Fig. 2 [18F]ICMT-11 uptake in
primary breast tumours. a Axial
CTand fused [18F]ICMT-11 PET/
CT images of primary breast
tumours in two patients, 1 and 2,
at baseline (pre-) and post-
chemotherapy. Low-level uptake
is noted. b Pre- and post-
chemotherapy SUV60ave and
SUV60max values of breast
tumours imaged at an early time-
point (24–48 h) or c late time-
point (2–14 days). Small changes
were seen pre- and post-
chemotherapy. d First-order
statistics were extracted using in-
house software under Matlab 15a
[The MathWorks(R)], and a subset
of features were selected to detect
changes in early and late imaged
breast tumours
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Fig. 3 Voxel–wise tumour [18F]ICMT-11 intensity histogram analysis
and blood cytokeratin-18 in all breast cancer patients. a PET-based voxel
intensity sorting (PVIS) histogram analysis in patients 1, 2, and 3. All
patients are late-imaged, (2–14 days) except patient 5* (early imaged 24–
48 h). The intensities of all voxels within the tumour volume of interest
(VOI) have been expressed as histogram plots of normalised voxel inten-
sities pre-and post-chemotherapy. These patients demonstrated a predom-
inant PVIS apoptotic signature with right shifts of all voxel intensities
within the tumour VOI post-chemotherapy. b PVIS histogram analysis in
patients 5 and 6, showing a predominant PVIS necrotic signature with
shift in voxel intensities to the left. Patient 14, showing no dominant
signature on PVIS histogram analysis. These results have been analysed
statistically and are represented through box-plot diagrams (minimum,
maximum, median, 10th and 90th percentile statistical parameters). The
differences in AUC shifts noted in each patient are shown in c, demon-
strating tumours with a predominant dominant PVIS apoptotic signature
(black) or dominant PVIS necrotic signature (white), and d associated
outcomes in all fifteen breast patients post 3 and 6 cycles of NCT.
Patients are shown as having SD (stable disease), PR (partial response)
or CR (complete response). * denotes patients who received trastuzumab
alongside their 4th–6th cycle of chemotherapy. Light grey shading (pa-
tients 1–4, who showed a predominant PVIS apoptotic signature). Mid-
grey shading (patients 5–13, who showed a predominant PVIS necrotic
signature). Dark grey shading (patients 14 and 15, who showed neither a
predominant apoptotic or necrotic shift). eCorresponding CK-18 analysis
(M65 and M30) pre-and post-chemotherapy in patients 1, 2, and 3.
Graphs highlight the variation in levels, with only patient 3 demonstrating
an increase in post-chemotherapy levels of M65 and M30. f CK-18 (M65
and M30) analysis in patients 5 and 6, showing no clear increase post-
chemotherapy, and patient 14, who despite showing no dominant signa-
ture on PVIS histogram analysis, was found to have an increase in M65
and M30 levels post-chemotherapy
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percentage cleaved caspase-3 showed variable baseline and post-
treatment expression. Cleaved caspase-3 expression was low at
baseline with levels below 0.45%; expression increased from a
mean of 0.13% (95% CI 0.12–0.13) to 0.81% (95% CI 0.79–
0.83). Such low levels of caspase-3 activation despite a mean
fold-change of 15.7% may prove difficult to detect by PET.
Longitudinal studies in lung cancer patients
[18F]ICMT-11 uptake in lung tumours at baseline
and post-chemotherapy
Three lesions from two lung cancer patients (a large left upper
lobe tumour in patient 16; a primary lesion in the right upper
thoracic mediastinum and a mediastinal lymph node in patient
17) were analysed at three time-points; the lesions were all
visible on PET (Fig. 5a). The interval between baseline
[18F]ICMT-11 PET/CT/MRI and start of chemotherapy in
both lung cancer patients was between 2 and 8 days.
Patients were scanned at 24 h and at 7 days after the first cycle
of chemotherapy. Median (range) SUV60ave and SUV60max
were 0.41 (0.33–0.61) and 0.85 (0.52–0.87) at baseline, 0.39
(0.35–0.62) and 0.87 (0.47–0.88) early after chemotherapy,
and 0.45 (0.42–0.66) and 0.94 (0.64–0.98) late after chemo-
therapy. First-order statistics showed no differences in the fea-
tures extracted. With regard to voxel-wise analysis, patient 16
demonstrated an initial PNDS shift followed by a PADS shift
(61%) to higher voxel intensities at 7 days post-chemotherapy
c
e
f
d
Fig. 3 (continued)
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(Fig. 5a and b). Patient 17, had a PNDS in the primary thoracic
lesion, at 24 h and 7 days post-chemotherapy (Fig. 5c and d).
Both patients had a partial response to combination platinum-
based chemotherapy (Fig. 5e and f).
Diffusion-weighted (DW) and dynamic contrast enhanced
(DCE) MRI in lung cancer
(please see Supplementary results).
Discussion
In the first patient study of the caspase 3/7-specific isatin
sulphonamide PET radiotracer, we show that the lack of sig-
nificant global tumour [18F]ICMT-11 dependent PETchanges,
despite some regional voxel changes, reflect a lack of signif-
icant apoptosis induction following chemotherapy. This study
to our knowledge is the first to investigate the use of a caspase
3/7-specific PET radiotracer for imaging of chemotherapy-
induced apoptosis in cancer.
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Fig. 4 Cleaved caspase-3 expression in breast patients. a Expression of
cleaved caspase-3 detected by immunohistochemistry in breast tissue
taken by USS-guided biopsy post-chemotherapy in patients with a
predominant PVIS apoptotic signature. b Similar cleaved caspase-3
expression in patients with a predominant PVIS necrotic signature no
change on PVIS. Arrows (black) demonstrate cleaved caspase-3
staining on tissue biopsy post-chemotherapy. c Graph indicates the
percentage (%) cleaved caspase-3 expression in breast tissue in all
patients taken at baseline (blue bars) and post-chemotherapy (yellow
bars). * denotes early imaged (24–48 h) breast patients
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Chemotherapy response has often been associated with
cell death via apoptosis [21, 23, 24]; however, such stud-
ies have often been semi-quantitative and based on biopsy
samples with variable output. Several studies have report-
ed that spatial and temporal heterogeneity exist in breast
and other cancers [31, 32]. Repeat biopsy of breast tissue
at a single point in time is not representative of the whole
tumour. Thus, approaches aiming to image whole-tumour
apoptosis for the purposes of assessing therapeutic re-
sponse (to chemotherapy, targeted therapies, and radio-
therapy) were embraced. These imaging methods include
MRI [20, 33], magnetic resonance spectroscopy (MRS)
[34], USS [35], novel fluorescence imaging [36], scintig-
raphy [11, 18] and PET [6, 10, 16, 17]. Studies using
c
d
Patient Radiological response (RECIST 1.1)
Post 3 cycles Post 4 cycles
16 PR PR
Patient Radiological response (RECIST 1.1)
Post 3 cycles Post 5 cycles
17 PR PR
b
a
e f
Patient 16 Patient 17
Baseline CT 24h CT 7d CT
Baseline PET/CT 24h PET/CT 7d PET/CT
Baseline CT 24h CT 7d CT
Baseline PET/CT 24h PET/CT 7d PET/CT
24h post-chemotherapy
7d post-chemotherapy
24h post-chemotherapy
7d post-chemotherapy
Fig. 5 Detection of tumour cell death in lung cancer by [18F]ICMT-11
PET/CT. Patient 16 (a) and Patient 17 (c) axial CT and fused [18F]ICMT-
11 PET/CT images of primary lung cancer at cancer at baseline, 24 h and
7 days post-chemotherapy. PVIS histogram analysis at 24 h and 7 days
post-chemotherapy in patient 16 (b) and 17 (d), with clinical outcomes (e
and f)
Eur J Nucl Med Mol Imaging (2018) 45:2285–2299 2295
[99mTc]Annexin V, in particular, led the way for nuclear
imaging of apoptosis [11, 19, 37].
In the current study, we report that caspase-3/7 activation as
determined by [18F]ICMT-11 was not a dominant mechanism
of pharmacological activity following chemotherapy in breast
cancer. Two pieces of information enabled us to reach this
conclusion. First, cytokeratin-18 analysis in blood samples, a
method that has been previously reported to have high sensi-
tivity and specificity for detecting apoptosis [38, 39], showed
a positive change— increased M30/M65 ratio— only in one
patient (patient 3). Indeed, Olofsson et al. indicated based on
their M30/M65 data that FEC chemotherapy, also used by us,
causes predominantly necrotic death compared for instance to
taxane-based therapy [39]. Whether necrotic death was sec-
ondary to apoptosis was not determined. Furthermore, the
absolute proportion of apoptotic cells in biopsy samples ob-
tained from patients soon after [18F]ICMT-11 PET scanning
was generally in the 1% range, albeit an increase from pre-
therapy levels (Fig. 4c). This low proportion of apoptotic cells
may not generally lead to detection by nuclear methods.While
cytokeratin-18 methodology can be influenced by apoptosis
of chemotherapy-sensitive healthy tissue [40], we were sur-
prised by the low proportion of apoptosis from histology. In
comparison to routine oncology nuclear medicine radio-
tracers, the (baseline) pre-chemotherapy uptake of
[18F]ICMT-11 in tumour was low, with SUV60max values
around 1. With simultaneous acquisition of anatomical infor-
mation, by CT in our case, segmentation of tumour is still
possible and in view of this, low baseline uptake presumably
representing the no/low apoptosis state is inconsequential.
However, SUV parameters did not change following treat-
ment, attributed to the low level of apoptosis seen in these
tumours. In preclinical studies, [18F]ICMT-11 demonstrated
high specificity to apoptosis versus necrosis [8, 29, 41]; thus,
it is unlikely that the lack of changes is a reflection of lack of
specificity. It is possible to rationalise a highly heterogeneous
response of tumours to chemotherapy whereby clusters of
tumours respond more avidly to the therapy than the bulk of
the tumour. Indeed, we demonstrate this phenomenon in pre-
clinical models of lung cancer imaged with [18F]ICMT-11
PET, whereby the global tumour tracer normalised uptake
value returned no changes following effective therapy. In con-
trast, PVIS histogram analysis showed a clear right shift over
48 h post-treatment, with a 1.5-fold increase in the number of
voxels having high intensity uptake [41]. Consequently, PVIS
analysis allows extraction of the Bcell-death^ signal by
allowing the capture of heterogeneous [18F]ICMT-11-detect-
able activated caspase-3/7 within the tumour, compared with
simple uptake values derived from the volume of interest.
The over-reliance on voxel-based analysis for apoptosis
data is predicated on pre-clinical studies for ICMT-11 [41]
and clinical studies with [18F]ML-10 [16, 17], intimating a
manner in which apoptosis data should be presented in view
of its heterogeneous presentation. All patients, except one,
responded to treatment; hence, we were unable to correlate
PADS in particular, but also PANS to clinical outcome. All
four patients with PADS responded to therapy; however, pa-
tients showing PANS or no change also responded to therapy,
indicating that PADS is not a pre-requisite for response in this
patient group. Notably, however, the only patient showing a
positive M30/M65 also showed the highest PADS. Equally,
we cannot infer a more appropriate time for [18F]ICMT-11
measurement, although the second window (2-14d) is perhaps
more practical.
The lack of ‘non-responders’ is a limitation of our study;
however, this could not be influenced due to the prospective
nature of the study; thus, all outcomes were reported. The
main aim — the investigation of the changes in ICMT-11
uptake and relationship with biochemical/histological
caspase-3 activity— was, however, not compromised.
It is worth considering the difficulties within this study both
from a logistics and scientific perspective. The timing of apo-
ptosis has been elusive and fraught with difficulties when
using functional imaging such as PET. Parton et al. [22] re-
ported apoptosis in tissue biopsies rising within 24 h of che-
motherapy in breast patients, a finding consistent with other
studies [21, 23]. Due to logistics of imaging and availability of
the patient, 24 h post-chemotherapy imaging was not feasible
in all patients. In our study cohort, patients underwent imaging
with [18F]ICMT-11 PET/CT at various time-points post-che-
motherapy. Two patients imaged at 24 h post-chemotherapy
failed to show an apoptotic dominant signature or significant
increase in caspase-3 expression.
Apoptosis may not be the sole mechanism of cell death in
treatment response. Although it is known to play a key role,
cell death can occur by necrosis, mitotic catastrophe, senes-
cence, autophagy, pyroptosis, and DNA damage [42]. As the
majority of patients in our study showed a dominant necrotic
or mixed apoptotic/necrotic signature phenotype, the balance
between apoptosis and necrosis may be one in favour of the
latter. This could in part, account for the lack of a predominant
apoptotic signal on PET and histology.
Longitudinal, multi-parametric imaging studies in the
lung cancer patients permitted us to verify simultaneously
[18F]ICMT-11, ADC as a measure of cell death, and DCE-
MRI as a measure of perfusion/permeability. The increase
in ADC values seen with DW-MRI in patient 16, 24 h and
7 days post-chemotherapy, infers increased cell death-
induced increases in water mobility as previously reported
[43]. This is consistent with the increase in tumour
[18F]ICMT-11 in the same patient. Conversely, the de-
crease in ADC variables in patient 17 may be linked to
increases in ECM constituents [44] that can accompany
response (necrosis, fibrosis, or mixed inflammatory infil-
trate) and associated cell swelling [43]. Accordingly, in
the two patients there appears to be congruence of
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[18F]ICMT-11 and ADC data. Significant changes in
perfusion/permeability could perturb PVIS measurements.
Assessment of the pharmacokinetics rate constant Ktrans
from the DCE-MRI study showed that perfusion/
permeability dynamics could not explain the [18F]ICMT-
11 dynamics within the time frame of the study. Beyond
this proof of concept study, future prospective studies in a
larger cohort should examine the role of [18F]ICMT-11 in
assessing chemotherapy response, to also include a fair
mix of responders and non-responders. The outcome of
the lung cancer cohort study when confirmed in a larger
cohort may support use of combined PET-MRI in moni-
toring ADC-detectable cell death and [18F]ICMT-11-de-
tectable caspase-3/7 activation.
Conclusion
In aggregate, initial studies using [18F]ICMT-11 were
promising in preclinical and first-in-man healthy volunteer
studies [8, 29, 41, 45]. We report the first use of
[18F]ICMT-11 in a small cohort of patients diagnosed with
breast or lung cancer and receiving first-line chemothera-
py. The results show that only a small proportion of apo-
ptosis was induced by drug treatment and that this level did
not induce global changes in tumour [18F]ICMT-11 uptake.
Voxel-wise analysis showed regional increases of
[18F]ICMT-11 intensity regions in some tumours, and
while patients having this phenotype responded to therapy,
it was not an exclusive marker of response. Thus, tumour
response could occur in the absence of predominant
chemotherapy-induced caspase-3/7 activation measured
non-invasively across entire tumour lesions in patients
with breast and lung cancer.
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